FYI - From the Medical Technology Stock Letter dated March 11, 1999
"One of the most obvious acquisition candidates is Cor Therapeutics. They have a product on the market, they are moving rapidly toward profitability, and their focus on cardiovascular disease is attractive to a company like Chiron, which has made a commitment to this sector. It is also worth noting that Chiron's Chief Scientific Officer, Rusty Williams, was the scientific founder of Cor. Once the stock gets moving so that Chiron would consider a reasonable premium over market, it is one of the most likely merger targets. Other companies among our recommended stocks which are particularly attractive merger targets are Onyx, ImmunoGen, Celtrix and maybe Imclone Systems."
.....In addition, Wall Street does not understand the huge potential of not only Integrilin, which is already approved, but of their oral anti-platelet drug, which could be another big product, and which has yet to be partnered. We cannot find words strong enough to tell you how much we love the stock at these prices. Corr is a buy under $18. |
